Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION

View through CrossRef
Objective: P2Y12 inhibitor monotherapy after a brief period of dual antiplatelet therapy (DAPT, a combination of aspirin and a P2Y12 inhibitor) can reduce bleeding without increasing ischemic harm after percutaneous coronary intervention (PCI). The impact of this approach among patients with hypertension remains unknown. We sought to examine the effect of P2Y12 inhibitor monotherapy versus DAPT among patients with hypertension undergoing PCI. Design and method: This is a post-hock analysis of the hypertension cohort in the SMART-CHOICE trial. The SMART-CHOICE trial was a randomized trial that compared P2Y12 inhibitor monotherapy after 3 months of DAPT with prolonged DAPT (12 months or longer) in patients who underwent PCI. The primary endpoint was Bleeding Academic Research Consortium (BARC) 2 to 5 bleeding. The composite ischemic endpoint was all-cause death, myocardial infarction, or stroke. Treatment effects were estimated according to presence of hypertension with formal interaction testing to assess for effect modification. Results: Patients with hypertension comprised 61.5% (n = 1,840) of the randomized cohort and were characterized by more frequent comorbidities. At 3 years after randomization, patients with hypertension experienced higher rates of all-cause death (3.9% vs 2.5%; p = 0.039), stroke (1.6% vs 0.6%; p = 0.014), or MACCE (6.8% vs 3.8%; p<0.001) but similar BARC types 2 to 5 bleeding (5.4% vs 4.9%; p = 0.601) compared with patients without hypertension. The incidence of BARC 2 to 5 bleeding was 2.9% and 7.8% among patients with hypertension randomized to P2Y12 inhibitor monotherapy versus DAPT [hazard ratio (HR): 0.382; 95% confidence interval (CI): 0.243 to 0.600; p<0.001]. However, P2Y12 inhibitor monotherapy was not associated with an increase in ischemic events compared with DAPT (7.2% vs. 6.5%; HR: 1.135; 95% CI: 0.767 to 1.679; p = 0.527) in patients with hypertension. In the overall trial population, there was no significant interaction between hypertension status and treatment group for the primary bleeding (adjusted p for interaction 0.835) or ischemic endpoints (adjusted p for interaction 0.707). Conclusions: P2Y12 inhibitor monotherapy is associated with significantly lower risk for bleeding events compared with DAPT, without any compromise in ischemic prevention, among patients with history of hypertension undergoing PCI.
Ovid Technologies (Wolters Kluwer Health)
Title: P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION
Description:
Objective: P2Y12 inhibitor monotherapy after a brief period of dual antiplatelet therapy (DAPT, a combination of aspirin and a P2Y12 inhibitor) can reduce bleeding without increasing ischemic harm after percutaneous coronary intervention (PCI).
The impact of this approach among patients with hypertension remains unknown.
We sought to examine the effect of P2Y12 inhibitor monotherapy versus DAPT among patients with hypertension undergoing PCI.
Design and method: This is a post-hock analysis of the hypertension cohort in the SMART-CHOICE trial.
The SMART-CHOICE trial was a randomized trial that compared P2Y12 inhibitor monotherapy after 3 months of DAPT with prolonged DAPT (12 months or longer) in patients who underwent PCI.
The primary endpoint was Bleeding Academic Research Consortium (BARC) 2 to 5 bleeding.
The composite ischemic endpoint was all-cause death, myocardial infarction, or stroke.
Treatment effects were estimated according to presence of hypertension with formal interaction testing to assess for effect modification.
Results: Patients with hypertension comprised 61.
5% (n = 1,840) of the randomized cohort and were characterized by more frequent comorbidities.
At 3 years after randomization, patients with hypertension experienced higher rates of all-cause death (3.
9% vs 2.
5%; p = 0.
039), stroke (1.
6% vs 0.
6%; p = 0.
014), or MACCE (6.
8% vs 3.
8%; p<0.
001) but similar BARC types 2 to 5 bleeding (5.
4% vs 4.
9%; p = 0.
601) compared with patients without hypertension.
The incidence of BARC 2 to 5 bleeding was 2.
9% and 7.
8% among patients with hypertension randomized to P2Y12 inhibitor monotherapy versus DAPT [hazard ratio (HR): 0.
382; 95% confidence interval (CI): 0.
243 to 0.
600; p<0.
001].
However, P2Y12 inhibitor monotherapy was not associated with an increase in ischemic events compared with DAPT (7.
2% vs.
6.
5%; HR: 1.
135; 95% CI: 0.
767 to 1.
679; p = 0.
527) in patients with hypertension.
In the overall trial population, there was no significant interaction between hypertension status and treatment group for the primary bleeding (adjusted p for interaction 0.
835) or ischemic endpoints (adjusted p for interaction 0.
707).
Conclusions: P2Y12 inhibitor monotherapy is associated with significantly lower risk for bleeding events compared with DAPT, without any compromise in ischemic prevention, among patients with history of hypertension undergoing PCI.

Related Results

Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract Introduction Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Dual Antiplatelet Therapy
Dual Antiplatelet Therapy
Antiplatelet agents have been utilized to enhance outcomes in patients with acute coronary syndrome for decades and are increasingly valued for their antithrombotic as well as anti...
Pretreatment with P2Y12 inhibitors in ST‐elevation myocardial infarction: A systematic review and meta‐analysis
Pretreatment with P2Y12 inhibitors in ST‐elevation myocardial infarction: A systematic review and meta‐analysis
AbstractBackgroundPretreatment with oral P2Y12 inhibitors is a standard practice for ST‐elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventi...

Back to Top